By Henry Ehrlich
This web site has coated the progress of dipilumab, a monoclonal antibody to deal with eczema, since earlier than it had a model identify. The primary sighting was in a presentation by Dr. Emma Guttman-Yassky of Mount Sinai. The earlier than and after photos, perfect accompaniment for a rooster dinner on the Harvard Membership, have been dramatic. Earlier than appeared like second and third diploma burns. After appeared bathing-suit worthy. Other than this miracle drug efficacy, the opposite topic was the retail price of the market model “Dupixent”. At $38,000, the worth tag was so excessive that Regeneron’s CEO Leonard Schleifer anticipated that insurance coverage firms would possibly reject protection and grow to be a problem so he created a hashtag #deniedRX that itchy sufferers might use to share tales of being shot down. Presumably there can be a groundswell of stress on the insurers.
I realized about this in a biotech podcast produced by STAT, a wonderful medical web site, known as The Readout Loud (extremely advisable for anybody within the enterprise of prescription drugs), and I appeared it up. I realized it’s not as straightforward for a giant firm to go viral as it’s for the standard no-talent actuality TV star. It solely collected 13 Tweets, the final of which was in March this yr, and a number of other of these have been about scandals that bore no relation to the drug.
Who is aware of? Perhaps Schliefer had visions of a trigger celebre on the order of Mylan and EpiPen. Nevertheless it’s one factor to ratchet an indispensable product as much as scandalous costs over a interval of years—dependent sufferers might be outraged–and one other to start out out scandalously priced after which mild a match, hoping the outrage would burst out. Actually, as the parents at STAT identified, this stunt was generated to spice up earnings. And it didn’t work; as of this previous spring, when each Regeneron and its accomplice Sanofi misplaced inventory market worth based mostly on disappointing Dupixent gross sales.
Good drug. Iffy enterprise mannequin.
Graphic by eczemaliving.com
Like this:Like Loading…
By Henry Ehrlich